joswe ivy syrup (10% hederacoside-c) 37 mg/5ml
الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - ivy standarized extract (10% hederacoside-c) 37 mg/5ml - (10% hederacoside-c) 37 mg/5ml
joswe ivy syrup (10% hederacoside-c) 37 mg/5ml
الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - ivy standarized extract (10% hederacoside-c) 37 mg/5ml - (10% hederacoside-c) 37 mg/5ml
herbion ivy lozenges lozenges
krka d.d. - ivy leaf dry extract - lozenges - 35mg
herbion ivy syrup syrup
krka d.d. - ivy leaf dry extract - syrup - 7mg/ml
activyl spot-on for extra large dogs over 40kg up to 60kg
intervet australia pty limited - indoxacarb - topical solution/suspension - indoxacarb oxadiazine active 195.0 g/l - parasiticides
activyl spot-on for large dogs over 20 kg up to 40 kg
intervet australia pty limited - indoxacarb - topical solution/suspension - indoxacarb oxadiazine active 195.0 g/l - parasiticides
activyl spot-on for very small dogs 1.5 kg up to 6.5 kg
intervet australia pty limited - indoxacarb - topical solution/suspension - indoxacarb oxadiazine active 195.0 g/l - parasiticides
activyl spot-on for medium dogs over 10 kg up to 20 kg
intervet australia pty limited - indoxacarb - topical solution/suspension - indoxacarb oxadiazine active 195.0 g/l - parasiticides
activyl spot-on for small dogs 6.6 kg up to 10 kg
intervet australia pty limited - indoxacarb - topical solution/suspension - indoxacarb oxadiazine active 195.0 g/l - parasiticides
polivy polatuzumab vedotin 30 mg powder for injection vial
roche products pty ltd - polatuzumab vedotin, quantity: 30 mg - injection, powder for - excipient ingredients: succinic acid; sodium hydroxide; sucrose; polysorbate 20 - polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).,polivy in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large b-cell lymphoma who are not candidates for hematopoietic stem cell transplant.